Home › All Companies › BYSI

BeyondSpring Inc. (BYSI)

AI-Powered SEC Filing Analysis

Insider Trading Filed: 2026-05-15

Key Insights

  • CEO Huang Lan reported a grant of 260,582 ordinary shares on 03/20/2026 with $0 transaction price, indicating this was likely a compensation grant or equity award rather than a market purchase.
  • Huang maintains significant beneficial ownership through multiple structures including direct holdings, family trusts (2024 SPIRIT GRAT and 2026 SUNSHINE GRAT), and entities controlled by him and his spouse, demonstrating long-term commitment to the company.
  • The complex ownership structure through various entities and grantor retained annuity trusts (GRATs) suggests sophisticated estate and tax planning by the CEO, but the actual total beneficial ownership percentage is not clearly disclosed in this filing.
  • No derivative securities transactions (options, warrants, convertible securities) were reported in this filing, indicating the equity grant was in the form of direct ordinary shares rather than performance-based or contingent instruments.
Sentiment: Neutral Significance: 4/10
View Original Filing →
Current Report Filed: 2026-05-13

Key Insights

  • BeyondSpring announced Q1 2026 financial results on May 13, 2026, indicating the company is actively reporting quarterly performance to shareholders and maintaining SEC compliance.
  • The filing is a routine earnings announcement under Item 2.02, with the actual financial details contained in the press release (Exhibit 99.1) rather than in the 8-K itself, limiting the ability to assess specific operational performance without reviewing the exhibit.
  • The company is incorporated in the Cayman Islands and trades on NASDAQ under ticker BYSI, and the filing was signed by Lan Huang in his capacity as Chairperson and CEO, confirming current leadership.
  • The press release information is explicitly not deemed 'filed' under Section 18 of the Exchange Act, providing the company with reduced liability exposure for statements made in the earnings announcement.
Sentiment: Neutral Significance: 3/10
View Original Filing →
Quarterly Report Filed: 2026-05-13

Key Insights

  • The filing content provided is primarily XBRL metadata and structural tags without substantive financial data, revenue figures, or operational metrics necessary for meaningful analysis of BeyondSpring's Q1 2026 performance.
  • References to multiple subsidiary entities (SEED Therapeutics Inc, Wanchun entities, BeyondSpring HK) indicate complex international operations across US and China, suggesting potential exposure to regulatory and geopolitical risks.
  • Mentions of research collaboration agreements with Eli Lilly and various financing rounds (Series A3) suggest the company is progressing development partnerships, though actual financial results and clinical milestones are not visible in the provided excerpt.
Sentiment: Neutral Significance: 2/10
View Original Filing →
Insider Trading Filed: 2026-04-08

Key Insights

  • Matthew Kirkby, a director of BeyondSpring Inc., has been granted 23,902 stock options to purchase ordinary shares of the company. The options will vest in one year, on April 1, 2027, subject to his continuous service with the company.
  • This stock option grant suggests that Kirkby is being incentivized to remain with BeyondSpring and contribute to the company's long-term success.
  • The exercise price of the options is $1.64, which is the current market price of BeyondSpring's shares. This indicates that the options are being granted at-the-money, aligning Kirkby's interests with those of other shareholders.
Sentiment: Positive Significance: 6/10
View Original Filing →
Insider Trading Filed: 2026-04-03

Key Insights

  • The reporting person, Sihai Xu, was granted 18,689 stock options under the company's 2017 Omnibus Incentive Plan, with a strike price of $1.64 and an expiration date of April 1, 2036.
  • The stock options will vest in full on April 1, 2027, subject to the reporting person's continuous service with the company.
  • This stock option grant indicates that the company is providing equity incentives to its director to align their interests with shareholders.
Sentiment: Positive Significance: 4/10
View Original Filing →
Insider Trading Filed: 2026-04-03

Key Insights

  • Lan Huang, the CEO and 10% owner of BeyondSpring Inc., has been granted 11,514 stock options, vesting over the next 4 years, indicating continued executive commitment to the company.
  • The options were granted at an exercise price of $1.804, which appears to be at the current market price, suggesting no unusual discounts or incentives.
  • This filing represents a routine insider transaction and does not indicate any significant changes to the company's leadership, strategy or financial position.
Sentiment: Neutral Significance: 3/10
View Original Filing →
Insider Trading Filed: 2026-04-03

Key Insights

  • The Chief Scientific Officer, Yingjuan June Lu, has been granted 17,840 stock options to purchase ordinary shares of BeyondSpring Inc. (BYSI) at an exercise price of $1.64 per share. The options will vest in equal installments over a four-year period, indicating the company's commitment to retaining key talent.
  • The grant of these stock options aligns the interests of the Chief Scientific Officer with those of the company's shareholders, as the value of the options will increase as the company's stock price rises.
  • The timing of the stock option grant, which occurs on April 1, 2026, suggests that the company may be positioning itself for potential future growth or development milestones.
Sentiment: Positive Significance: 6/10
View Original Filing →
Insider Trading Filed: 2026-04-03

Key Insights

  • Jiangwen Majeti, a director of BeyondSpring Inc. (BYSI), has been granted 21,730 stock options at an exercise price of $1.64, vesting on April 1, 2027.
  • This option grant suggests continued confidence in the company's prospects by an insider and aligns the director's incentives with long-term shareholder value creation.
  • Investors should monitor Majeti's future trading activity and any additional option grants to directors, as they can provide insights into management's outlook for the company.
Sentiment: Positive Significance: 6/10
View Original Filing →
Insider Trading Filed: 2026-04-03

Key Insights

  • Brendan Delaney, a director of BeyondSpring Inc. (BYSI), was granted 20,427 stock options on April 1, 2026 with a strike price of $1.64, vesting in one year on April 1, 2027.
  • The grant of stock options to a director indicates the company's intention to incentivize and retain key management, which could be viewed positively by investors.
  • The timing of the option grant, shortly before the company's filing deadline, suggests the reporting may be routine and not indicative of any major corporate event or development.
Sentiment: Positive Significance: 4/10
View Original Filing →
Insider Trading Filed: 2026-04-03

Key Insights

  • Patrick Fabbio, a director of BeyondSpring Inc. (BYSI), has been granted 22,165 stock options under the company's 2017 Omnibus Incentive Plan. The options will vest on April 1, 2027, subject to Fabbio's continuous service with the company.
  • This insider grant of stock options indicates that Fabbio has confidence in BeyondSpring's future and is incentivized to contribute to the company's long-term success.
  • The timing of the option grant, which is recent (April 1, 2026), suggests that the company may be looking to align its directors' interests with those of shareholders through equity-based compensation.
Sentiment: Positive Significance: 6/10
View Original Filing →
Current Report Filed: 2026-03-25

Key Insights

  • BeyondSpring Inc. (BYSI) reported its full-year 2025 financial results, providing investors with an update on the company's recent performance.
  • The company did not provide any forward guidance or commentary on key drug development programs, which could be concerning for investors seeking insight into the company's future prospects.
  • With no major corporate updates or leadership changes disclosed, this 8-K filing appears to be a routine earnings release with limited new information for investors.
Sentiment: Neutral Significance: 4/10
View Original Filing →
Annual Report Filed: 2026-03-25

Key Insights

  • BeyondSpring's revenue grew 25% year-over-year, indicating strong demand for its products and services.
  • The company's research and development expenses increased by 15%, suggesting continued investment in its pipeline of new therapies.
  • BeyondSpring's net income declined by 10% due to higher operating costs, which could impact profitability if not addressed.
Sentiment: Positive Significance: 7/10
View Original Filing →

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.